LIPO vs. CING, GNPX, THAR, ZVSA, SEEL, CPHI, LGVN, ARTL, PCSA, and SNGX
Should you be buying Lipella Pharmaceuticals stock or one of its competitors? The main competitors of Lipella Pharmaceuticals include Cingulate (CING), Genprex (GNPX), Tharimmune (THAR), ZyVersa Therapeutics (ZVSA), Seelos Therapeutics (SEEL), China Pharma (CPHI), Longeveron (LGVN), Artelo Biosciences (ARTL), Processa Pharmaceuticals (PCSA), and Soligenix (SNGX). These companies are all part of the "pharmaceutical preparations" industry.
Cingulate (NASDAQ:CING) and Lipella Pharmaceuticals (NASDAQ:LIPO) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, profitability, community ranking, valuation, analyst recommendations, institutional ownership, earnings and risk.
In the previous week, Cingulate had 3 more articles in the media than Lipella Pharmaceuticals. MarketBeat recorded 3 mentions for Cingulate and 0 mentions for Lipella Pharmaceuticals. Lipella Pharmaceuticals' average media sentiment score of 0.27 beat Cingulate's score of 0.00 indicating that Cingulate is being referred to more favorably in the media.
Cingulate has a net margin of 0.00% compared to Cingulate's net margin of -1,025.93%. Lipella Pharmaceuticals' return on equity of 0.00% beat Cingulate's return on equity.
Lipella Pharmaceuticals has higher revenue and earnings than Cingulate.
Cingulate presently has a consensus target price of $8.00, suggesting a potential upside of 808.99%. Lipella Pharmaceuticals has a consensus target price of $2.00, suggesting a potential upside of 181.29%. Given Lipella Pharmaceuticals' higher possible upside, analysts plainly believe Cingulate is more favorable than Lipella Pharmaceuticals.
Cingulate has a beta of -0.95, meaning that its stock price is 195% less volatile than the S&P 500. Comparatively, Lipella Pharmaceuticals has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500.
41.3% of Cingulate shares are held by institutional investors. Comparatively, 74.3% of Lipella Pharmaceuticals shares are held by institutional investors. 38.4% of Cingulate shares are held by company insiders. Comparatively, 39.6% of Lipella Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Cingulate received 5 more outperform votes than Lipella Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Lipella Pharmaceuticals an outperform vote while only 66.67% of users gave Cingulate an outperform vote.
Summary
Lipella Pharmaceuticals beats Cingulate on 8 of the 14 factors compared between the two stocks.
Get Lipella Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for LIPO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LIPO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lipella Pharmaceuticals Competitors List
Related Companies and Tools
